Opus Genetics FY2024 EPS Estimate Reduced by HC Wainwright

Opus Genetics, Inc. (NASDAQ:IRD) – HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for Opus Genetics in a report released on Wednesday, November 13th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($1.22) per share for the year, down from their previous forecast of ($1.11). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.11) per share. HC Wainwright also issued estimates for Opus Genetics’ Q4 2024 earnings at ($0.34) EPS, FY2025 earnings at ($1.03) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.53) EPS and FY2028 earnings at ($0.23) EPS.

Opus Genetics (NASDAQ:IRD) last released its earnings results on Tuesday, November 12th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.01. Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%. The company had revenue of $3.87 million during the quarter, compared to analysts’ expectations of $1.17 million.

Opus Genetics Stock Performance

Shares of IRD stock opened at $1.06 on Friday. The firm has a market cap of $33.46 million, a P/E ratio of -0.97 and a beta of 0.22. Opus Genetics has a 1-year low of $0.97 and a 1-year high of $3.40.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.